41 articles for M Shen
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
44
Identification of ML251, a Potent Inhibitor of T. brucei and T. cruzi Phosphofructokinase.
National Center For Advancing Translational Sciences
83
Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.
University of Kansas Specialized Chemistry Center
2
Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.
Astrazeneca
4
Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors.
National Center For Advancing Translational Sciences
38
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)¿isoleucine(315) mutant.
Chinese Academy of Sciences
76
2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
National Human Genome Research Institute
4
Structure-activity study on a series ofa-glutamic acid scaffold based compounds as new ADAMTS inhibitors.
Chinese Academy of Sciences
52
Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).
National Human Genome Research Institute
24
Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
Lexicon Pharmaceuticals
33
5-Fluorocytosine derivatives as inhibitors of deoxycytidine kinase.
Lexicon Pharmaceuticals
35
Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.
National Human Genome Research Institute
27
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
National Human Genome Research Institute
32
Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis.
National Human Genome Research Institute
7
Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.
Astrazeneca R&D Boston
21
Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor.
AstraZeneca
3
Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay.
Chinese Academy of Sciences
20
1,2,4-Oxadiazolidin-3,5-diones and 1,3,5-triazin-2,4,6-triones as cytosolic phospholipase A2alpha inhibitors.
Wyeth Research
38
Identification of TUL01101: A Novel Potent and Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis.
Zhuhai United Laboratories
70
Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors.
National Center For Advancing Translational Sciences
50
Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
Astrazeneca
22
Structure-activity relationships of indole cytosolic phospholipase A(2)alpha inhibitors: substrate mimetics.
Wyeth Research
95
Discovery and Optimization of 2
National Center For Advancing Translational Sciences
6
Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase.
Astrazeneca
25
Discovery and Structure-Activity Relationship Study of (
Dana-Farber Cancer Institute
2
Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Sichuan University and Collaborative Innovation Center of Biotherapy
20
Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.
Dana-Farber Cancer Institute
1
Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
China Pharmaceutical University
10
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Frederick National Laboratory For Cancer Research
70
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.
National Center For Advancing Translational Sciences
10
Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
Sichuan University and Collaborative Innovation Center
36
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
Astrazeneca
3
Multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib (Bestazomib) and preparation method and application thereof
Shandong Hubble Kisen Biological Technonlogy Co.
52
Indoleamine 2,3-dioxygenase inhibitor, method for preparation and use thereof
Nanjing Huawe Medicine Technology Group
88
1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
Incyte
180
Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
Abbvie
7
Novel synthesis of dihydropyrimidines for a-glucosidase inhibition to treat type 2 diabetes: in vitro biological evaluation and in silico docking.
Comsats Institute of Information Technology